Mariner
VNDA icon

Mariner’s Vanda Pharmaceuticals VNDA Stock Holding History

Mariner’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$552K Buy
79,854
+63,025
+375% +$486K ﹤0.01% 2420
2025
Q4 		$146K Sell
16,829
-566
-3% -$3.12K ﹤0.01% 3251
2025
Q3 		$86.8K Buy
+17,395
New +$80.5K ﹤0.01% 3385

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mariner's VNDA Position: Q1 2026 in Review

Mariner increased its Vanda Pharmaceuticals (VNDA) stake by 375% in Q1 2026, buying an estimated $486K and bringing the position to 79,854 shares worth $552K. The position accounts for ﹤0.01% of the portfolio, ranked #2420.

Mariner first reported a position in VNDA in Q3 2025 and has held it in 3 quarters since. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • Mariner held 79,854 shares of Vanda Pharmaceuticals worth $552K as of Q1 2026.
  • Mariner bought 63,025 Vanda Pharmaceuticals shares in Q1 2026, an estimated $486K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #2420 holding.
  • Mariner first reported a position in Vanda Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.